Prevention of Postmenopausal Bone Loss and Treatment of Osteoporosis

ABSTRACT

Osteoporosis is now recognized as an increasingly prevalent disorder throughout the world. Fragility fractures and their subsequent short- and long-term complications are the adverse outcomes of this disease that is essentially silent until fractures occur. Given that the presence of one fragility fracture is an important predictor of the risk of subsequent fractures, prevention of the first fracture is critical whenever possible. Two key elements in fracture prevention that are discussed in this article are the attainment of optimal peak bone mass and the prevention of bone loss at menopause, with the major focus on the prevention of postmenopausal bone loss.

KEYWORDS

Osteoporosis - fracture - prevention - peak bone mass - postmenopause

REFERENCES

• 1 Peacock M, Turner C H, Econs M J, Foroud T. Genetics of osteoporosis.  Endocr Rev. 2002;  23 303-326
• 2 Koo W W, Warren L. Calcium and bone health in infants.  J Neonatal Network. 2003;  22 23-37
• 3 Weaver C M. The growing years and prevention of osteoporosis in later life.  Proc Nutr Soc. 2000;  59 303-306
• 4 Prentice A. Diet, nutrition and the prevention of osteoporosis.  Public Health Nutr. 2004;  7 227-243
• 5 McClung M, Clemmesen B, Daifotis A et al.. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.  Ann Intern Med. 1998;  128 253-261
• 6 Lindsay R, Gallagher J C, Kleerekoper M, Pickar J H. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.  JAMA. 2002;  287 2668-2676
• 7 Johnston Jr C C, Bjarnason N H, Cohen F J et al.. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.  Arch Intern Med. 2000;  160 3444-3450
• 8 Mortensen L, Charles P, Bekker P J, Digennaro J, Johnston Jr C C. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.  J Clin Endocrinol Metab. 1998;  83 396-402
• 9 Glazier M G, Bowman M A. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy.  Arch Intern Med. 2001;  161 1161-1172
• 10 Bjarnason N H, Alexandersen P, Christiansen C. Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent.  Bone. 2002;  30 637-642
• 11 Christiansen C, Lindsay R. Estrogens, bone loss and preservation.  Osteoporos Int. 1990;  1 7-13
• 12 U.S. Preventive Services Task Force . Screening for osteoporosis in postmenopausal women: recommendations and rationale.  Ann Intern Med. 2002;  137 526-528
• 13 Anonymous. Consensus development conference: prophylaxis and treatment of osteoporosis.  Am J Med. 1991;  90 107-110
• 14 Osteoporosis Prevention .Diagnosis, and Therapy. NIH Consensus Statement. 2000 March 27-29 17: 1-36 Available at: http://consensus.nih.gov/cons/111/111_statement.htm
• 15 Wehrli F W, Saha P K, Gomberg B R et al.. Role of magnetic resonance for assessing structure and function of trabecular bone.  Top Magn Reson Imaging. 2002;  13 335-355
• 16 Anonymous. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva; World Health Organization Technical Report Series 843 1994
• 17 Black D M, Cummings S R, Melton III L J. Appendicular bone mineral and a woman's lifetime risk of hip fracture.  J Bone Miner Res. 1992;  7 639-646
• 18 Faulkner K G, von Stetten E, Miller P. Discordance in patient classification using T-scores.  J Clin Densitom. 1999;  2 343-350
• 19 Siris E S, Miller P D, Barrett-Connor E et al.. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment.  JAMA. 2001;  286 2815-2822
• 20 Miller P D, Siris E S, Barrett-Connor E. et al . Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment.  J Bone Miner Res. 2002;  17 2222-2230
• 21 Stone K L, Seeley D G, Lui L Y et al.. Osteoporotic Fractures Research Group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures.  J Bone Miner Res. 2003;  18 1947-1954
• 22 Garnero P, Sornay-Rendu E, Claustrat B, Delmas P D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.  J Bone Miner Res. 2000;  15 1526-1536
• 23 Looker A C, Bauer D C, Chesnut III C H et al.. Clinical use of biochemical markers of bone remodeling: current status and future directions.  Osteoporos Int. 2000;  11 467-480
• 24 Luukinen H, Kakonen S M, Pettersson K et al.. Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin.  J Bone Miner Res. 2000;  15 2473-2478
• 25 Delmas P D, Eastell R, Garnero P, Seibel M J, Stepan J. Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation.  Osteoporos Int. 2000;  11 S2-17
• 26 Melton III L J, Crowson C S, O'Fallon W M, Wahner H W, Riggs B L. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction.  J Bone Miner Res. 2003;  18 312-318
• 27 Bruyere O, Collette J, Delmas P et al.. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women.  Maturitas. 2003;  44 259-265
• 28 Hannon R A, Eastell R. Biochemical markers of bone turnover and fracture prediction.  J Br Menopause Soc. 2003;  9 10-15
• 29 Garnero P, Sornay-Rendu E, Claustrat B, Delmas P D. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.  J Bone Miner Res. 2000;  15 1526-1536
• 30 Bjarnason N H, Sarkar S, Duong T, Mitlak B, Delmas P D, Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.  Osteoporos Int. 2001;  12 922-930
• 31 Hochberg M C, Greenspan S, Wasnich R D, Miller P, Thompson D E, Ross P D. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.  J Clin Endocrinol Metab. 2002;  87 1586-1592
• 32 Eastell R, Barton I, Hannon R A, Chines A, Garnero P, Delmas P D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.  J Bone Miner Res. 2003;  18 1051-1056
• 33 Jilka R L. Cytokines, bone remodeling, and estrogen deficiency: a 1998 update.  Bone. 1998;  23 75-81
• 34 Russell R G, Rogers M J. Bisphosphonates: from the laboratory to the clinic and back again.  Bone. 1999;  25 97-106
• 35 Cranney A, Tugwell P, Wells G, Guyatt G. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology.  Endocr Rev. 2002;  23 496-507
• 36 Cranney A, Wells G, Willan A et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.  Endocr Rev. 2002;  23 508-516
• 37 Cranney A, Tugwell P, Adachi J et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.  Endocr Rev. 2002;  23 517-523
• 38 Cranney A, Tugwell P, Zytaruk N et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies or postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.  Endocr Rev. 2002;  23 524-528
• 39 Wells G, Tugwell P, Shea B et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta- analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women.  Endocr Rev. 2002;  23 529-539
• 40 Cranney A, Tugwell P, Zytaruk N et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis.  Endocr Rev. 2002;  23 540-551
• 41 Shea B, Wells G, Cranney A et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis.  Endocr Rev. 2002;  23 552-559
• 42 Papadimitropoulos E, Wells G, Shea B et al.. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. VIII. Meta-analysis of the efficacy of Vitamin D treatment in preventing osteoporosis in postmenopausal women.  Endocr Rev. 2002;  23 560-569
• 43 Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis.  Endocr Rev. 2002;  23 570-578
• 44 Barrett-Connor E, Wehren L E, Siris E S et al.. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.  Menopause. 2003;  10 412-419
• 45 Banks E, Beral V, Reeves G, Balkwill A, Barnes I. Million Women Study Collaborators. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women.  JAMA. 2004;  291 2212-2220